Last reviewed · How we verify
sodium chloride AGUETTANT 0.9%
At a glance
| Generic name | sodium chloride AGUETTANT 0.9% |
|---|---|
| Sponsor | Association Athletes For Transparency |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy and Safety of Intravenous Lidocaine Versus Placebo in Patients Receiving Morphine-rachi Analgesia (PHASE3)
- Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE) (PHASE2)
- Evaluation of Erythroferrone as a New Biomarker of Erythropoesis Stimulating Agents (PHASE1)
- Impact Of Antioxidant Micronutrients On Intensive Care Unit (ICU) Outcome (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- sodium chloride AGUETTANT 0.9% CI brief — competitive landscape report
- sodium chloride AGUETTANT 0.9% updates RSS · CI watch RSS
- Association Athletes For Transparency portfolio CI